Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...1516171819202122232425...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema-A Two-Year Matched Comparative Study. (Pubmed Central) -  Feb 12, 2022   
    During the 2-year treatment periods, the T&E group received more injections than the PRN group (11.0 ± 3.2 vs. 6.2 ± 2.0; p < 0.001), while the PRN group had more recurrence of macular edema than the T&E group (71 vs. 41%; p = 0.015). After 2-year ranibizumab treatment for DME, better visual and anatomical improvement and less recurrence of macular edema were achieved in the T&E group, with more injections administered.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal:  A review of neovascular glaucoma. Etiopathogenesis and treatment. (Pubmed Central) -  Feb 4, 2022   
    Anyway, the best treatment is prevention, so we must be very attentive at patients with risk factors for developing the NVG. Abbreviations: NVG = neovascular glaucoma, ICA = iridocorneal angle, IOP = intraocular pressure, TM = trabecular meshwork, AH = aqueous humor, AC = anterior chamber, PRP = panretinal photocoagulation, VEGF = vascular endothelial growing factor, Anti-VEGF = anti- vascular endothelial growing factor, PAS = peripheral anterior synechiae, CRVO = central retinal vein occlusion, PDR = proliferative diabetic retinopathy, DR = diabetic retinopathy, OIS = ocular ischemic syndrome, CRAO = central retinal artery occlusion, ROP = retinopathy of prematurity, FEVR = familial exudative vitreoretinopathy, PVR = proliferative vitreoretinopathy, MMPs = matrix metalloproteinases, VEGFR = vascular endothelial growing factor receptor, PDGF = platelet-derived growth factor, PIGF = placental growth factor, NRP = neuropilins, HIF = hypoxia-inducible factor, SDF1 = stromal cell-derived factor 1, DDL4 = delta like ligand 4, NICD = Notch intracellular domain, TIMMPs = tissue inhibitors of matrix metalloproteinases, ANGPT = angiopoietin, Tie 2 = tyrosine-protein kinase receptor for angiopoietins, IGF-1 = insulin-like growth factor 1, RPE = retinal pigment epithelium, IL = interleukin, TNF = tumor necrosis factor, bFGF = basic fibroblast growth factor, TGF = transforming growth factor, HGF = hepatocyte growth factor, TNFR 2 = tumor necrosis factor receptor 2, OIR = oxygen induced retinopathy, NVI = neovascularization of the iris, NVA = neovascularization of the iridocorneal angle, FA = fluorescein angiography, RAPD = relative afferent pupillary defect, CNP = capillary non-perfusion, NVE = neovascularization elsewhere in the retina, NVD = neovascularization of the optic disc, FFA = fundus fluorescein angiography, OCTA = optical coherence tomography angiography, B-scan US = B-scan ocular ultrasound, AS-OCT = anterior segment optical coherence tomography, ARC = anterior retinal cryotherapy, FDA = food and drug administration, United States of America, BVZ = bevacizumab, RBZ = ranibizumab, AFB = aflibercept, AMD/ ARMD = age related macular degeneration, DME = diabetic macular edema, GDDs = glaucoma drainage devices, MMC = mitomycin C, 5-FU = 5-fluorouracil, AGV = Ahmed glaucoma valve, AADI = Aurolab aqueous drainage implant, MIGS = minimally invasive glaucoma surgery, BCVA = best corrected visual acuity, TVT = Tube versus Trabeculectomy study, MPC = micro-pulse cyclophotocoagulation.
  • ||||||||||  Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
    New trial, Real-world evidence, Real-world:  Anti-VEGF in Real-world (clinicaltrials.gov) -  Feb 2, 2022   
    P=N/A,  N=1000, Recruiting, 
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Retrospective data, Review, Journal:  Ranibizumab and conbercept for treating wet age-related macular degeneration in China: A systematic review and meta-analysis. (Pubmed Central) -  Feb 2, 2022   
    The effects of ranibizumab on uncorrected visual acuity, best corrected visual acuity, and central macular thickness were not significantly different from those of conbercept. Conbercept is associated with a lower risk of increased intraocular pressure and regression of choroidal neovascularization compared with ranibizumab.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Ranibizumab for the treatment of diabetic retinopathy. (Pubmed Central) -  Feb 1, 2022   
    A comprehensive presentation of randomized clinical trials evaluating ranibizumab for DR indicates that it is effective and safe, offering improvement of DR severity in both non-proliferative and proliferative form. However, there is no general consensus regarding the exact treatment regimen in patients with DR, while the effect of ranibizumab on the progression of retinal ischemia remains unclear.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    To study the effect of process parameters on titre and expression ratio of heavy and light chains of ranibizumab in Escherichia coli (Pacific Ballroom: Section 19 (Marriott Marquis San Diego Marina)) -  Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_12168;    
    The product identification was performed with LC-MS and expression level was quantified using RP HPLC, product quality and impurity level was also quantified by RP HPLC and further analysed by LC-MS. The optimum range was predicted for each parameter and found to be satisfactory for obtaining higher protein titre with equal expression and minimal impurities.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Ethanol as an additive enhances expression of Ranibizumab in Escherichia coli: Impact on cellular physiology and transcriptome (Pacific Ballroom: Section 18 (Marriott Marquis San Diego Marina)) -  Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_235;    
    LC-MS confirmed correct disulfide bond formation and Surface plasmon resonance confirmed the formation of active recombinant protein via binding to its target VEGF. Transcriptomic analysis and RT-qPCR validation indicated that changes in membrane properties and DNA synthesis results in growth, gene amplification and enhances synthesis of inducible proteins in case of the optimized medium.
  • ||||||||||  LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    Biomarker, Retrospective data, Journal:  Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results. (Pubmed Central) -  Jan 27, 2022   
    In addition, patients with recurrence, large lesion, and cluster polyps had worse final visual acuity than those without these factors. CVI and CVH may be used to predict recurrence of PCV.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Retrospective data, Journal:  Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan. (Pubmed Central) -  Jan 27, 2022   
    This retrospective study included 182 eyes of 172 patients managed in the vitreoretinal unit between 2016 and 2019 who were treated with intravitreal anti-VEGF bevacizumab (1.25 mg/0.05 ml) with at least 1 year of follow-up...Visual acuity gain was recorded in patients who had intravitreal anti-VEGF injections in 1 year. It is recommended that patients should have more than one injection.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Macular atrophy development in neovascular age-related macular degeneration. (Pubmed Central) -  Jan 26, 2022   
    Monitoring aqueous KRT8 may aid early determination of therapeutic effects of IVR in neovascular AMD patients and reflect the health conditions of retinal pigment epithelium. No abstract available
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal, HEOR, Real-world evidence:  Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion. (Pubmed Central) -  Jan 26, 2022   
    We found statistically significant differences between complete and incomplete responders on the average number of injections during the second year (2.46 ± 2.18 compared to 5.43 ± 1.27; p = 0.007) and change of the BCVA and CMT between both groups (p < 0.001) at 6, 12, 18 and 24 months. T&E seems to be effective in MO secondary to BRVO, improving visual function and decreasing CMT, with less need for injections.
  • ||||||||||  LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Retrospective data, Journal:  Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs. (Pubmed Central) -  Jan 26, 2022   
    After the first year, central retinal thickness in treatment-naïve eyes was significantly reduced. Regular treatment of wet age-related macular degeneration as part of the treatment program achieves functional stabilization and significant morphological improvement over a long-term, three-year follow-up, with significantly fewer injections needed after the first year of treatment.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Real-Life Data of Patients with Exudative Age-Related Macular Degeneration. (Pubmed Central) -  Jan 26, 2022   
    Anatomical and functional success was achieved with anti-VEGF treatment after fewer injections and visits than have been reported in randomized, controlled, clinical studies in the literature. The number of injections and visits recorded in this study was consistent with the data of other real-life studies.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
    Journal:  Tocilizumab and Aflibercept as a Treatment Option for Refractory Macular Edema after Acute Retinal Necrosis. (Pubmed Central) -  Jan 26, 2022   
    A combination treatment of tocilizumab, an interleukin-6 receptor inhibitor, and intravitreal aflibercept was successful to control the CME. In selected patients with treatment-refractory CME following ARN a therapy with tocilizumab and intravitreal aflibercept might be considered.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Factors Associated With the Presence of Foveal Bulge in Eyes With Resolved Diabetic Macular Edema. (Pubmed Central) -  Jan 26, 2022   
    A total of 165 eyes with complete integrity of ellipsoid zone (EZ) at the fovea and resolved DME were divided into two groups according to the presence of FB at 6 months after intravitreal injection of ranibizumab treatment...At 6 months, better BCVA and longer OS length were significantly correlated with the existence of FB (all P < 0.05). Factors associated with the presence of FB after the resolution of DME include younger age, better baseline BCVA and lower baseline CFT, and better post-treatment BCVA and longer post-treatment OS length.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Risk of Myocardial Infarction, Stroke, or Death in New Users of Intravitreal Aflibercept Versus Ranibizumab: A Nationwide Cohort Study. (Pubmed Central) -  Jan 26, 2022   
    Factors associated with the presence of FB after the resolution of DME include younger age, better baseline BCVA and lower baseline CFT, and better post-treatment BCVA and longer post-treatment OS length. Aflibercept and ranibizumab appear to have similar safety profiles with respect to the risk of MI, stroke, or death under real-world conditions of use.
  • ||||||||||  HLX04-O (bevacizumab biosimilar) - Fosun Pharma, Essex Bio / Technology
    Enrollment open:  Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD (clinicaltrials.gov) -  Jan 25, 2022   
    P3,  N=388, Recruiting, 
    Aflibercept and ranibizumab appear to have similar safety profiles with respect to the risk of MI, stroke, or death under real-world conditions of use. Not yet recruiting --> Recruiting
  • ||||||||||  Nevanac (nepafenac) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Prophylaxis of macular edema after cataract surgery in diabetic patients, topical Nepafenac versus intravitreal Ranibizumab. (Pubmed Central) -  Jan 21, 2022   
    In postoperative visits, cystoid macular edema occurred in three patients (7.9%) in Nepafenac group, one patient (2.7%) in Ranibizumab group, and seven patients (17.07%) in control group. Both postoperative topical Nepafenac and intra-operative intra-vitreal Ranibizumab are effective adjunctive to phacoemulsification in diabetic patients for prophylaxis of macular edema.